Florescu, Marie <br/><br/>
A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21.  [electronic resource] 

 -  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer  Jun 2008 
 - 590-8 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1556-1380 
<br/><br/><label>Standard No.: </label>10.1097/JTO.0b013e3181729299  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Dose-Response Relationship, Drug<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Ontario--epidemiology<br/>Prognosis<br/>Proportional Hazards Models<br/>Protein Kinase Inhibitors--administration & dosage<br/>Quinazolines--administration & dosage<br/>Survival Rate<br/>Time Factors